Therapeutic targets in liver transplantation: Angiotensin II in nonsteatotic grafts and angiotensin-(1-7) in steatotic grafts

American Journal of Transplantation

Volumn 9, Issue 3, 2009, Pages 439-451

  Alfany Fernandez, I ^a,b   Casillas Ramirez, A ^a,b   Bintanel Morcillo, M ^a,b   Brosnihan, K B ^c   Ferrario, C M ^c   Serafin, A ^d   Rimola, A ^a,e   Rodes J ^a,e   Rosello Catafau J ^a,b,f   Peralta, C ^a,b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b CSIC   (Spain)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f INST D INVESTIGACIONS B   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANGIOTENSIN II; ANGIOTENSIN[1-7]; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FATTY LIVER; GENE OVEREXPRESSION; GRAFT SURVIVAL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIVER BLOOD FLOW; LIVER GRAFT; LIVER INJURY; LIVER PROTECTION; LIVER TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSINOGEN; ANIMALS; APOPTOSIS; FATTY LIVER; GRAFT SURVIVAL; HEALTH; LIVER TRANSPLANTATION; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PEPTIDE FRAGMENTS; RATS; RECEPTORS, ANGIOTENSIN;

EID: 60649089834     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02521.x     Document Type: Article

References (45)

1. Imber CJ, St Peter SD, Handa A, Friend PJ. Hepatic steatosis and its relationship to transplantation. Liver Transpl 2002 8 : 415 423.
2. Crowley H, Lewis WD, Gordon F, Jenkins R, Khettry U. Steatosis in donor and transplant liver biopsies. Hum Pathol 2000 31 : 1209 1213.
3. D'Alessandro AM, Kalayoglu M, Sollinger HW et al. The predictive value of donor liver biopsies for the development of primary nonfunction after orthotopic liver transplantation. Transplantation 1991 51 : 157 163.
4. Ploeg RJ, D'Alessandro AM, Knechtle SJ et al. Risk factors for primary dysfunction after liver transplantation-a multivariate analysis. Transplantation 1993 55 : 807 813.
5. Bader M, Peters J, Baltatu O, Müller DN, Luft FC, Ganten D. Tissue renin-angiotensin systems: New insights from experimental animal models in hypertension research. J Mol Med 2001 79 : 76 102.
6. Guo L, Richardson KS, Tucker LM, Doll MA, Hein DW, Arteel GE. Role of the renin-angiotensin system in hepatic ischemia reperfusion injury in rats. Hepatology 2004 40 : 583 589.
7. Casillas-Ramirez A, Amine-Zaouali M, Massip-Salcedo M et al. Inhibition of angiotensin II action protects rat steatotic livers against ischemia-reperfusion injury. Crit Care Med 2008 36 : 1256 1266.
8. Keidar S, Kaplan M, Gamliel-Lazarovich A. ACE2 of the heart: From angiotensin I to angiotensin (1-7). Cardiovasc Res 2007 73 : 463 469.
9. Santos RA, Ferreira AJ. Pharmacological effects of AVE 0991, a nonpeptide angiotensin-(1-7) receptor agonist. Cardiovasc Drug Rev 2006 24 : 239 246.
10. Santos RA, Simoes e Silva AC, Maric C et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003 100 : 8258 8263.
11. Tallant EA, Ferrario CM, Gallagher PE. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol 2005 289 : H1560 H1566.
12. Ferreira AJ, Santos RA. Cardiovascular actions of angiotensin-(1-7). Braz J Med Biol Res 2005 38 : 499 507.
13. Ferrario CM. Angiotensin-converting enzyme 2 and angiotensin-(1-7): An evolving story in cardiovascular regulation. Hypertension 2006 47 : 515 521.
14. Reudelhuber TL. A place in our hearts for the lowly angiotensin 1-7 peptide Hypertension 2006 47 : 811 815.
15. Loot AE, Roks AJ, Henning RH et al. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 2002 105 : 1548 1550.
16. Benter IF, Yousif MH, Cojocel C, Al-Maghrebi M, Diz DI. Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am J Physiol Heart Circ Physiol 2007 292 : H666 H672.
17. Pereira RM, Dos Santos RA, Teixeira MM et al. The renin-angiotensin system in a rat model of hepatic fibrosis: Evidence for a protective role of Angiotensin-(1-7). J Hepatol 2007 46 : 674 681.
18. Carrasco-Chaumel E, Roselló-Catafau J, Bartrons R et al. Adenosine monophosphate-activated protein kinase and nitric oxide in rat steatotic liver transplantation. J Hepatol 2005 43 : 997 1006.
19. Kamada N, Calne RY. Orthotopic liver transplantation in the rat. Technique using cuff for portal vein anastomosis and biliary drainage. Transplantation 1979 28 : 47 50.
20. Bayorh MA, Eatman D, Walton M, Socci RR, Thierry-Palmer M, Emmett N. A-779 attenuates angiotensin-(1-7) depressor response in salt-induced hypertensive rats. Peptides 2002 23 : 57 64.
21. Schulman D, Latchman DS, Yellon DM. Urocortin protects the heart from reperfusion injury via upregulation of p42/p44 MAPK signaling pathway. Am J Physiol Heart Circ Physiol 2002 283 : H1481 H1488.
22. Selzner M, Rüdiger HA, Sindram D, Madden J, Clavien PA. Mechanisms of ischemic injury are different in the steatotic and normal rat liver. Hepatology 2000 32 : 1280 1288.
23. Amersi F, Buelow R, Kato H et al. Upregulation of heme oxygenase-1 protects genetically fat Zucker rat livers from ischemia/reperfusion injury. J Clin Invest 1999 104 : 1631 1639.
24. Pan CH, Lin JL, Lai LP, Chen CL, Stephen Huang SK, Lin CS. Downregulation of angiotensin converting enzyme II is associated with pacing-induced sustained atrial fibrillation. FEBS Lett 2007 581 : 526 534.
25. Natori S, Selzner M, Valentino KL et al. Apoptosis of sinusoidal endothelial cells occurs during liver preservation injury by a caspase-dependent mechanism. Transplantation 1999 68 : 89 96.
26. Singh R, Singh AK, Alavi N, Leehey DJ. Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose. J Am Soc Nephrol 2003 14 : 873 880.
27. Senanayake PD, Moriguchi A, Kumagai H, Ganten D, Ferrario CM, Brosnihan KB. Increased expression of angiotensin peptides in the brain of transgenic hypertensive rats. Peptides 1994 15 : 919 926.
28. Nakamoto H, Ferrario CM, Fuller SB, Robaczewski DL, Winicov E, Dean RH. Angiotensin-(1-7) and nitric oxide interaction in renovascular hypertension. Hypertension 1995 25 : 796 802.
29. Fernández L, Carrasco-Chaumel E, Serafín A et al. Is ischemic preconditioning a useful strategy in steatotic liver transplantation Am J Transplant 2004 4 : 888 899.
30. Kazuo H, Nishida T, Seiyama A et al. Recovery of blood flow and oxygen transport after temporary ischemia of rat liver. Am J Physiol 1998 275 : H243 H249.
31. Längle F, Steininger R, Waldmann E et al. Improvement of cardiac output and liver blood flow and reduction of pulmonary vascular resistance by intravenous infusion of L-arginine during the early reperfusion period in pig liver transplantation. Transplantation 1997 63 : 1225 1233.
32. Serafín A, Roselló-Catafau J, Prats N, Gelpí E, Rodés J, Peralta C. Ischemic preconditioning affects interleukin release in fatty livers of rats undergoing ischemia/reperfusion. Hepatology 2004 39 : 688 698.
33. Selzner N, Selzner M, Jochum W, Clavien PA. Ischemic preconditioning protects the steatotic mouse liver against reperfusion injury: An ATP dependent mechanism. J Hepatol 2003 39 : 55 61.
34. Zingarelli B, Szabó C, Salzman AL. Reduced oxidative and nitrosative damage in murine experimental colitis in the absence of inducible nitric oxide synthase. Gut 1999 45 : 199 209.
35. Spät A, Enyedi P, Hajnóczky G, Hunyady L. Generation and role of calcium signal in adrenal glomerulosa cells. Exp Physiol 1991 76 : 859 885.
36. Ohyama K, Yamano Y, Chaki S, Kondo T, Inagami T. Domains for G-protein coupling in angiotensin II receptor type I: Studies by site-directed mutagenesis. Biochem Biophys Res Commun 1992 189 : 677 683.
37. So T, Nakashima Y, Imamura M, Arakawa K. Effects of local inhibition of the cardiac renin-angiotensin system with CV-11974 in a canine ischaemia-reperfusion model. Clin Exp Pharmacol Physiol 1998 25 : 503 509.
38. Masuko H, Jin MB, Horiuchi H et al. Protective effect of agiotensin II type I receptor antagonist, CV-11974, on ischemia and reperfusion injury of the liver. Transplantation 2001 71 : 1034 1039.
39. Li X, Meng Y, Wu P, Zhang Z, Yang X. Angiotensin II and Aldosterone stimulating NF-kappaB and AP-1 activation in hepatic fibrosis of rat. Regul Pept 2007 138 : 15 25.
40. Cross TG, Scheel-Toellner D, Henriquez NV, Deacon E, Salmon M, Lord JM. Serine/threonine protein kinases and apoptosis. Exp Cell Res 2000 256 : 34 41.
41. Liang T, Xu S, Yu J, Shen K, Li D, Zheng S. Activation pattern of mitogen-activated protein kinases in early phase of different size liver isografts in rats. Liver Transpl 2005 11 : 1527 1532.
42. Liang TB, Man K, Kin-Wah Lee T et al. Distinct intragraft response pattern in relation to graft size in liver transplantation. Transplantation 2003 75 : 673 678.
43. Cursio R, Filippa N, Miele C, Van Obberghen E, Gugenheim J. Involvement of protein kinase B and mitogen-activated protein kinases in experimental normothermic liver ischaemia-reperfusion injury. Br J Surg 2006 93 : 752 761.
44. Vickers C, Hales P, Kaushik V et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002 277 : 14838 14843.
45. Ferdinandy P, Schulz R. Nitric oxide, superoxide and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. Br J Pharmacol 2003 138 : 532 543.